[Characteristics of and risk factors for interstitial pneumonia due to TS-1(R) capsule administration-case reviews from a drug use results survey on Non-Small Cell Lung cancer patients and spontaneous reports].

A drug use results survey for the TS-1(R)capsule was conducted on patients with non-small cell lung cancer. A total of 1,784 patients were registered for the survey, 1,669 of whomwere evaluated for safety. The incidence of adverse drug reactions was 67.9%(1,134/1,669). The overall incidence of interstitial pneumonia was 1.38%(23/1,669), while it was 1.34% in patients treated with TS-1(R) alone(14/1,046). The risk factors for interstitial pneumonia according to this survey included allergic predisposition, concomitant diseases(including interstitial pneumonia), past medical history(including interstitial pneumonia), and combination with anticancer drugs(excluding cisplatin). Among the spontaneous reports of interstitial pneumonia as an adverse drug reaction from physicians, test images were available in 39 cases. These images were analyzed by the Safety Review Committee for interstitial pneumonia, consisting of external medical experts. In addition, the imaging patterns, settings of occurrence, and patient's backgrounds were reviewed. Twenty-five of the 39 cases were assessed to be possible interstitial pneumonia, of which 10 were confirmed to have an imaging pattern of diffuse alveolar damage. Based on the above findings, it is essential to check the patient's medical history for conditions such as lung disorder through a medical interview and an imaging test, prior to starting treatment with TS-1(R).